title: Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
abstract: Bladder cancer-specific oncolytic adenovirus Ad/PSCAE/UPII/E1A, carrying E1A gene regulated by human Uroplakin II (UPII) promoter and prostate stem cell antigen enhancer (PSCAE), could kill bladder tumor cells preferentially. The aim of this study was to examine the effects of Ad/PSCAE/UPII/E1A combined with cisplatin on human bladder cancer cells and to identify the underlying mechanisms. The combined effects of Ad/PSCAE/UPII/E1A and cisplatin on EJ, 5637, and BIU-87 bladder cancer cells were evaluated by MTT cell proliferation assay. Cell apoptosis was detected by flow cytometry with fluorescein isothiocyanate-conjugated annexin V (annexin V-FITC) and propidium iodide staining. The activation of the caspase pathway and the expression of Bcl-2 family proteins were determined by western blot assay. Ad/PSCAE/UPII/E1A adenovirus vector could infect bladder cancer cell lines selectively and induce growth inhibition effectively. Of note, the combination treatment of cisplatin and Ad/PSCAE/UPII/E1A could inhibit the proliferation of bladder cancer cells significantly compared with the "alone" treatment. Furthermore, Ad/PSCAE/UPII/E1A plus cisplatin combined treatment resulted in enhanced apoptosis in bladder cancer cells. The enhanced antitumor effects in vitro elicited by Ad/PSCAE/UPII/E1A plus cisplatin were closely related to the increased Fas expression and cleavage of caspase-8 and Bid and decrease in the ratio of anti- to pro-apoptotic proteins followed by activation of caspase-9 and caspase-3, which may contribute to the activation of extrinsic and intrinsic apoptotic pathways. Our results indicate that the combination of Ad/PSCAE/UPII/E1A with cisplatin exerts a synergistic antitumor effect on human bladder cancer cells and is a potential combined treatment strategy for bladder cancer.
authors.affiliation: School of Life Sciences, Lanzhou University, Lanzhou, 730000, Gansu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Yunxin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jinxia
authors.initials: J
authors.lastname: Zhao
authors.forename: Erlong
authors.initials: E
authors.lastname: Xiao
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Lu
authors.forename: Shengjun
authors.initials: S
authors.lastname: Fu
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D017500:Adenovirus E1A Proteins / Q000235:genetics*; D000951:Antigens, Neoplasm / Q000235:genetics; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D020169:Caspases / Q000378:metabolism; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology*; D003131:Combined Modality Therapy; D005434:Flow Cytometry; D058851:GPI-Linked Proteins / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D066298:In Vitro Techniques; D009363:Neoplasm Proteins / Q000235:genetics; D050130:Oncolytic Virotherapy; D011401:Promoter Regions, Genetic / Q000235:genetics; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D060170:Uroplakin II / Q000235:genetics
chemical_list: D017500:Adenovirus E1A Proteins; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D058851:GPI-Linked Proteins; D009363:Neoplasm Proteins; C110843:PSCA protein, human; D060170:Uroplakin II; D020169:Caspases; D002945:Cisplatin
references.citation: Mol Cell Biochem. 2007 Oct;304(1-2):315-23
references.pmid: 17577631
references.citation: J Clin Oncol. 1999 Jan;17(1):409-22
references.pmid: 10458260
references.citation: Oncogene. 2008 May 15;27(22):3081-90
references.pmid: 18071311
references.citation: Clin Cancer Res. 2000 Nov;6(11):4422-31
references.pmid: 11106263
references.citation: Cancer Surv. 1993;17:189-217
references.pmid: 8137341
references.citation: Annu Rev Genet. 1999;33:29-55
references.pmid: 10690403
references.citation: Cancer Gene Ther. 2011 Mar;18(3):176-88
references.pmid: 21052098
references.citation: N Engl J Med. 1987 Jun 4;316(23):1435-40
references.pmid: 2437455
references.citation: Cell. 1993 Aug 27;74(4):609-19
references.pmid: 8358790
references.citation: Nat Rev Cancer. 2007 Aug;7(8):573-84
references.pmid: 17625587
references.citation: Cancer. 1989 Dec 15;64(12):2448-58
references.pmid: 2819654
references.citation: Cancer Chemother Pharmacol. 1985;15(3):283-9
references.pmid: 2414023
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5299-312
references.pmid: 15328165
references.citation: Cancer Gene Ther. 2008 Jan;15(1):40-50
references.pmid: 18034197
references.citation: Cancer Res. 1996 Aug 1;56(15):3431-5
references.pmid: 8758907
references.citation: Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
references.pmid: 11525387
references.citation: Acta Pharmacol Sin. 2009 Apr;30(4):467-77
references.pmid: 19270721
references.citation: Anticancer Res. 1998 Sep-Oct;18(5A):3421-6
references.pmid: 9858918
references.citation: Mol Ther. 2001 Jul;4(1):13-21
references.pmid: 11472101
references.citation: Med Hypotheses. 1999 Aug;53(2):130-5
references.pmid: 10532707
references.citation: J Natl Cancer Inst Monogr. 1993;(15):83-8
references.pmid: 7912534
references.citation: Hum Gene Ther. 1999 Jul 1;10(10):1721-33
references.pmid: 10428217
references.citation: J Urol. 2012 Dec;188(6):2391-7
references.pmid: 23088985
references.citation: Cancer Res. 2001 Jun 1;61(11):4405-13
references.pmid: 11389068
references.citation: Cell. 1998 Aug 21;94(4):481-90
references.pmid: 9727491
references.citation: Cancer Res. 2009 Dec 1;69(23):8910-7
references.pmid: 19903849
references.citation: J Urol. 1985 Mar;133(3):403-7
references.pmid: 4038749
references.citation: Annu Rev Immunol. 1998;16:395-419
references.pmid: 9597135
references.citation: J Gen Virol. 2002 Mar;83(Pt 3):491-502
references.pmid: 11842243
references.citation: Pharm Weekbl Sci. 1985 Oct 25;7(5):173-80
references.pmid: 3906559
references.citation: Cancer Res. 2001 Nov 1;61(21):7882-8
references.pmid: 11691808
references.citation: J Immunol. 1992 Apr 1;148(7):2207-16
references.pmid: 1545126
references.citation: J Clin Invest. 2000 Apr;105(7):847-51
references.pmid: 10749561
references.citation: Cancer Res. 2003 Jan 15;63(2):382-5
references.pmid: 12543791
references.citation: Urol Oncol. 2003 May-Jun;21(3):197-205
references.pmid: 12810206
references.citation: J Mol Med (Berl). 2002 Mar;80(3):163-75
references.pmid: 11894142
references.citation: Cancer Res. 2002 Jun 15;62(12):3438-47
references.pmid: 12067986
references.citation: Cancer Gene Ther. 2010 Jan;17(1):11-9
references.pmid: 19662088
references.citation: Eur J Cancer. 2001 Dec;37(18):2310-23
references.pmid: 11720823
references.citation: N Engl J Med. 1995 Apr 13;332(15):1004-14
references.pmid: 7885406
references.citation: Mol Ther. 2000 Nov;2(5):485-95
references.pmid: 11082322
references.citation: Cytometry. 1996 Apr 1;23(4):303-11
references.pmid: 8900473
references.citation: Am J Pathol. 2000 Nov;157(5):1415-30
references.pmid: 11073801
references.citation: Gene Ther. 2012 Nov;19(11):1065-74
references.pmid: 22218302
references.citation: Cancer Res. 1997 Jul 1;57(13):2559-63
references.pmid: 9205053
references.citation: Biochem Biophys Res Commun. 2002 Aug 30;296(4):792-8
references.pmid: 12200117
references.citation: Science. 2004 Jul 30;305(5684):626-9
references.pmid: 15286356
references.citation: Mol Cell. 2005 Feb 18;17(4):525-35
references.pmid: 15721256
references.citation: Clin Cancer Res. 2000 Mar;6(3):798-806
references.pmid: 10741699
references.citation: Gene Ther. 2001 Jan;8(2):89-98
references.pmid: 11313778
references.citation: Cancer Res. 2001 Aug 15;61(16):6012-9
references.pmid: 11507044
references.citation: Int J Cancer. 1995 Sep 4;62(5):599-604
references.pmid: 7665232
references.citation: J Clin Invest. 2000 Sep;106(6):763-71
references.pmid: 10995787
references.citation: Nat Med. 2001 Jul;7(7):781-7
references.pmid: 11433341
references.citation: Cell. 1998 Aug 21;94(4):491-501
references.pmid: 9727492